Rachel Katzenellenbogen named co-leader of CPC research program at IU Simon Comprehensive Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Rachel Katzenellenbogen was named a co-leader of the Cancer Prevention and Control research program at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center. 

She serves along with Susan Rawl and Todd Skaar.

A member of the program since 2018, Katzenellenbogen is the chief of the Division of Adolescent Medicine in the Department of Pediatrics, associate professor of pediatrics and of microbiology and immunology, and the Richard E. and Pauline P. Klingler Scholar in Pediatrics at IU School of Medicine. She is also the Chuck and Tina Pagano Scholar at the cancer center.

Katzenellenbogen’s cancer research focuses on the fundamental way human papillomavirus drives cancer development and progression, how that drive is common to all cancers or is unique to this infection-associated cancer, and identifying ways to detect and disrupt these pathways to intervene early in treatment.

Before joining IU, Katzenellenbogen was an associate professor of pediatrics at the University of Washington and Seattle Children’s Research Institute. 

Table of Contents

YOU MAY BE INTERESTED IN

Earlier this week, Robert F. Kennedy Jr. was confirmed as secretary of Health and Human Services amid many resignations at federal health agencies and cancellations of NIH and NCAB meetings. All of this happened at a time when the Trump administration is reportedly preparing to fire thousands of HHS workers.
Fifty-four years ago, in his State of the Union Message in January 1971, President Nixon proposed a visionary and vigorous new challenge.  He said “The time has come in America when the same kind of concentrated effort that split the atom and took man to the moon” should be applied to finding a cure for cancer.  He followed up by requesting an appropriation of $100 million, and the promise to ask for whatever additional funds could be effectively used.  

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login